



Date: 30.05.2018

To,
Listing Department,
Dept. of Corporate Services,
Bombay Stock Exchange Limited,
P.J. Towers, Dalal Street, Fort,
Mumbai: 400 001.

To,
General Manager,
National Stock Exchange of India Ltd.,
Exchange Plaza, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai: 400 051.

Dear Sir/Madam,

Ref.:- Scrip Code - 532908 Scrip ID-SHARONBIO

Sub: - Financial Results for the quarter and year ended on March 31, 2018.

Pursuant to Regulation 33 of SEBI (Listing Obligations Disclosure Requirement) Regulations, 2015, enclosed please find herewith Standalone Audited Financial Results of the Company for the quarter and year ended on March 31, 2018, approved at the meeting held on May 30, 2018 along with the following:

- i) The Auditors Report issued on Standalone Audited Financial Results of the Company for the quarter and year ended on March 31, 2018 by M/s E.A. Patil & Associates LLP, (Firm Registration No. 117371W/W100092) Statutory Auditors of the Company.
- ii) The Declaration pursuant to Regulation 33(3) (d) of SEBI (Listing Obligations Disclosure Requirement), 2015 with respect to Audit Report with unmodified opinion.

The meeting commenced at 2:00pm and concluded at 7:30 pm.

Thanking You,

Yours faithfully,
For Sharon Bio-Medicine Limited


Deepali Bhatia
Company Secretary & Compliance officer

Adm. Off. : 312, C Wing, BSEL Tech Park, Sector - 30(A), Vashi, Navi Mumbai - 400 705.
Tel.: 91 22 - 67944000, Fax : 91 22 - 67944001
www.sharonbio.com

CIN NO. L24110MH1989PLC052251

Caring for relationships



Sharon

BIO-MEDICINE LTD.

An ISO-9001:2000
Certified Company



Extract of Standalone Audited financial Results for the year ended March 31, 2018

(₹ in Lacs)

SR. NO.	PARTICULARS	Quarter Ended			Year Ended	
		31/03/2018	31/12/2017	31/03/2017	31/03/2018	31/03/2017
		Audited	Unaudited	Unaudited	Audited	Audited
1	Total Revenue from Operations	3,703.07	4,055.22	4,076.03	13,076.38	16,017.18
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(25.45)	75.33	284.62	(436.65)	(2,001.59)
3	Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	(674.69)	69.17	(1,076.10)	(10,129.89)	(19,596.50)
4	Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	(674.69)	69.17	(507.42)	(10,129.89)	(16,589.42)
5	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and other Comprehensive Income (after tax)]	(633.36)	65.27	(506.50)	(10,100.27)	(16,600.20)
6	Paid-up Equity Share Capital (Face value of Rs.2/- each)					
7	Earnings Per Share (of Rs.2/- each) (for continuing and discontinued operations) (not annualised)					
	a) Basic (in Rs.)	(0.53)	0.05	(0.43)	(8.49)	(13.96)
	b) Diluted (in Rs.)	(0.53)	0.05	(0.43)	(8.49)	(13.96)

Notes :

1 The above is an extract of the detailed format of the Standalone Financial Results for the year ended March 31, 2018 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of these Financial Results are available on the Stock Exchange website, www.nseindia.com and www.bseindia.com, and on the Company's website www.sharonbio.com.

2 The above audited standalone financial results were approved in the meeting held on May 30, 2018.

3 The Government of India introduced the Goods & Services Tax (GST) with effect from July 01, 2017. Accordingly, in compliance with Indian Accounting Standards (Ind AS) 18 - 'Revenue', Revenue from Operations for the quarter ended September 30, 2017, December 31, 2017 and March 31, 2018 is provided net of GST. Revenue from Operations of earlier periods included excise duty which is now subsumed in GST. Revenue from Operations for the year ended March 31, 2018 includes excise duty upto June 30, 2017.

4 The Company adopted Indian Accounting Standards ("Ind AS") from April 1, 2017 with transition date of April 1, 2016 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 - Interim financial reporting prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India.

For Sharon Bio-Medicine Ltd.

Sd/

Kaushik Banerjee

Chief Executive Officer

Place : Mumbai.

Date : 30.05.2018

REGISTERED OFFICE & WORKS : W-34 & 34/1, MIDC, Talaja,
Dist.Raigad, Maharashtra (India).

CORP.: C-310/312, BSEL Tech Park, Opp. Vashi-Railway Station, Navi Mumbai - 400 703.

E-mail : investor_complaints@sharonbio.com, Website : www.sharonbio.com